Advertisement

Topics

Yondelis Plus “PARP” Inhibitor Olaparib in Sarcoma is Feasible

13:09 EDT 10 Oct 2018 | Cancer Connect

The Lancet: Italian researches report on the advancement of Yondelis plus Olaparib for treatment of Sarcoma

Original Article: Yondelis Plus “PARP” Inhibitor Olaparib in Sarcoma is Feasible

NEXT ARTICLE

More From BioPortfolio on "Yondelis Plus “PARP” Inhibitor Olaparib in Sarcoma is Feasible"

Advertisement
Quick Search
Advertisement
Advertisement